Aysegül Ilhan‐Mutlu
YOU?
Author Swipe
View article: Zolbetuximab and the novel biomarker claudin 18.2 in the treatment of gastroesophageal adenocarcinoma
Zolbetuximab and the novel biomarker claudin 18.2 in the treatment of gastroesophageal adenocarcinoma Open
Summary Systemic chemotherapy remains the standard treatment for advanced gastroesophageal cancer, typically combining a fluoropyrimidine with oxaliplatin. Despite recent advances through biomarker-driven therapies, overall prognosis remai…
View article: Lack of association between prior or concurrent malignancies and overall survival in gastroesophageal cancer: evidence from a large European single-center cohort
Lack of association between prior or concurrent malignancies and overall survival in gastroesophageal cancer: evidence from a large European single-center cohort Open
Background History of malignant disease is a common exclusion criterion in clinical cancer trials, yet data on the impact of cancer survivorship on outcome in gastroesophageal cancer patients are scarce. Methods Retrospective association a…
View article: Lymphovascular Invasion (LVI) Correlates with Systemic Immune-Inflammation Index (SII) in Adenocarcinoma of the Gastroesophageal Junction (AEG): Implications for Prognostic Stratification
Lymphovascular Invasion (LVI) Correlates with Systemic Immune-Inflammation Index (SII) in Adenocarcinoma of the Gastroesophageal Junction (AEG): Implications for Prognostic Stratification Open
Adenocarcinoma of the gastroesophageal junction (AEG) is an aggressive cancer with rising incidence and poor long-term survival despite multimodal treatment. Reliable preoperative prognostic markers are lacking. Methods: The study is based…
View article: Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study
Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study Open
View article: Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns
Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns Open
The treatment of metastasized gastroesophageal adenocarcinoma largely depends on molecular profiling based on immunohistochemical procedures. Therefore, the examination of HER2, PD-L1, and dMMR/MSI is recommended by the majority of clinica…
View article: Highlights on gastroesophageal tumors: the comeback of FLOT
Highlights on gastroesophageal tumors: the comeback of FLOT Open
Summary This article aims to summarize the highlights of the two largest global congresses of 2024 with respect to gastroesophageal tumors. The triplet chemotherapy combination known as FLOT (5-fluorouracil, leucovorin, oxaliplatin, doceta…
View article: Personalized targeted glioblastoma therapies by ex vivo drug screening: Study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT)
Personalized targeted glioblastoma therapies by ex vivo drug screening: Study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT) Open
Background Novel approaches to guide personalized treatment in glioblastoma are urgently needed. Given the poor predictive value of genetic biomarkers in glioblastoma, we are conducting a prospective clinical trial to investigate the novel…
View article: KRAS: Finally a druggable target in oncology?
KRAS: Finally a druggable target in oncology? Open
View article: State-of-the-art therapy and innovative treatment strategies in esophageal squamous cell cancer
State-of-the-art therapy and innovative treatment strategies in esophageal squamous cell cancer Open
Summary Recent advances in the development of new therapeutic agents and the execution of numerous randomized controlled trials have changed the landscape of systemic therapy approaches in patients with esophageal squamous cell cancer (ESC…
View article: Overexpression of Fibroblast Growth Factor 8 Is a Predictor of Impaired Survival in Esophageal Squamous Cell Carcinoma and Correlates with ALK/EML4 Alteration
Overexpression of Fibroblast Growth Factor 8 Is a Predictor of Impaired Survival in Esophageal Squamous Cell Carcinoma and Correlates with ALK/EML4 Alteration Open
FGF8, ALK, and EML4 have been identified as promising biomarkers in a number of malignancies. The aim of this study was to examine the prognostic role of FGF8, ALK, and EML4 in esophageal squamous cell carcinoma (ESCC). Methods: Consecutiv…
View article: Correction to: Association of family history with patient characteristics and prognosis in a large European gastroesophageal cancer cohort
Correction to: Association of family history with patient characteristics and prognosis in a large European gastroesophageal cancer cohort Open
View article: Association of family history with patient characteristics and prognosis in a large European gastroesophageal cancer cohort
Association of family history with patient characteristics and prognosis in a large European gastroesophageal cancer cohort Open
View article: Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases Open
Background Brain metastases (BM) are a devastating complication of HER2-positive metastatic breast cancer (BC) and treatment strategies providing optimized local and systemic disease control are urgently required. The antibody-drug conjuga…
View article: Upper-GI highlights from ASCO and ASCO-GI 2023 meetings: changing paradigm in treatment sequence
Upper-GI highlights from ASCO and ASCO-GI 2023 meetings: changing paradigm in treatment sequence Open
Summary The annual meeting of the American Society of Medical Oncology (ASCO) was held as usual in Chicago, while the meeting focused on gastrointestinal tumors, ASCO-GI, was held in San Francisco. In particular, ASCO-GI included many phas…
View article: HER2 in focus—gastric cancer
HER2 in focus—gastric cancer Open
View article: Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma Open
Summary There is an unmet need for the treatment of patients with HER2-positive gastroesophageal tumors whose disease progressed on a first-line trastuzumab-based regimen. Several prospective trials took a targeted approach and evaluated v…
View article: Systemic inflammatory biomarkers as prognostic tools in patients with gastroesophageal adenocarcinoma
Systemic inflammatory biomarkers as prognostic tools in patients with gastroesophageal adenocarcinoma Open
View article: Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction
Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction Open
Objective The aim of this study was to investigate the prognostic role of plasma platelet count (PLT), mean platelet volume (MPV), and the combined COP-MPV score in patients with resectable adenocarcinomas of the gastroesophageal junction.…
View article: Emerging molecular drugs for the treatment of gastroesophageal tumors
Emerging molecular drugs for the treatment of gastroesophageal tumors Open
View article: Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction
Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction Open
Objective: Aim of this study was to investigate the prognostic role of plasma platelet count (PLT), mean platelet volume (MPV) and the combined COP-MPV score in patients with resectable adenocarcinomas of the gastroesophageal junction. Bac…
View article: Supplementary Figure 7 from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs
Supplementary Figure 7 from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs Open
Supplementary Figure 7 shows correlation of NDRG1 expression with tumor growth in mouse and human samples.
View article: Supplementary Figure 5 from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs
Supplementary Figure 5 from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs Open
Supplementary Figure 5 shows cell cycle analysis.
View article: Supplementary Figure 4 from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs
Supplementary Figure 4 from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs Open
Supplementary Figure 4 shows IVIS results.
View article: Supplementary Figure 1 from Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
Supplementary Figure 1 from Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma Open
Time from randomization to new brain lesions in AVAiL Trial
View article: Data from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs
Data from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs Open
Specific biological properties of those circulating cancer cells that are the origin of brain metastases (BM) are not well understood. Here, single circulating breast cancer cells were fate-tracked during all steps of the brain metastatic …
View article: Supplementary Figure 5 from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs
Supplementary Figure 5 from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs Open
Supplementary Figure 5 shows cell cycle analysis.
View article: Supplementary Table 1 from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs
Supplementary Table 1 from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs Open
Supplementary Table 1 shows entire gene list.
View article: Supplementary Figure 1 from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs
Supplementary Figure 1 from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs Open
Supplementary Figure 1 A-C shows loss of PKH26 over time. Supplementary Figure 1 D shows an additional example of a slow cycling cells with remaining PKH26 staining in vivo
View article: Data from Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
Data from Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma Open
Patients with nonsquamous non–small cell lung cancer (nsNSCLC; largely lung adenocarcinoma) are at high risk of developing brain metastases. Preclinical data suggested that anti–VEGF-A therapy may prevent the formation of nsNSCLC brain met…
View article: Supplementary Figure 7 from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs
Supplementary Figure 7 from Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs Open
Supplementary Figure 7 shows correlation of NDRG1 expression with tumor growth in mouse and human samples.